<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029233</url>
  </required_header>
  <id_info>
    <org_study_id>Occ2019_01</org_study_id>
    <nct_id>NCT04029233</nct_id>
  </id_info>
  <brief_title>The PROOF Trial - Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke in Patients With Cryptogenic Stroke and High Risk PFO</brief_title>
  <acronym>PROOF</acronym>
  <official_title>Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke in Patients With Cryptogenic Stroke and High Risk PFO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of&#xD;
      recurrent ischemic stroke in patients who have had a cryptogenic stroke due to a presumed&#xD;
      paradoxical embolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to investigate stroke recurrence rates after interventional PFO closure with&#xD;
      an Occlutech PFO Occluder in patients who have experienced at least one ischemic cryptogenic&#xD;
      stroke attributed to patent foramen ovale (PFO) who have high risk PFO, i.e. large PFO (≥2&#xD;
      mm), or PFO of any size and atrial septal aneurysm (ASA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the safety and tolerability of the Occlutech PFO occluder by assesssing the incidence of SADEs.</measure>
    <time_frame>in the 1 year following implantation.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To demonstrate the medium-term effectiveness of the Occlutech PFO Occluder by assessing the rate of ischemic strokes.</measure>
    <time_frame>in the 5 years following implantation</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">863</enrollment>
  <condition>Stroke</condition>
  <condition>PFO - Patent Foramen Ovale</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlutech PFO Occluder</intervention_name>
    <description>The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.</description>
    <other_name>Occlutech Figulla Flex II Occluder</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll patients of either sex, aged ≥18 and ≤60 years, with at least one&#xD;
        event of cryptogenic ischemic stroke in the last 6 months. Patients must have a high risk&#xD;
        PFO indicated for device-assisted closure; either large PFO (≥2 mm), or PFO of any size and&#xD;
        ASA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and ≤60 years&#xD;
&#xD;
          -  At least one event of cryptogenic ischemic stroke in the last 6 months&#xD;
&#xD;
          -  Presence of a PFO indicated for device-assisted closure (in compliance with the&#xD;
             Instruction for Use) confirmed by common practice procedures&#xD;
&#xD;
          -  A large PFO (maximum separation of the septum primum from the secundum) of ≥2 mm&#xD;
             confirmed by common practice procedures, or an ASA defined by common practice&#xD;
             procedures as septum primum excursion of ≥10 mm&#xD;
&#xD;
          -  Life expectancy of at least 1 year&#xD;
&#xD;
          -  Ability to speak fluently and to understand the language in which the study is being&#xD;
             conducted&#xD;
&#xD;
          -  Written, informed consent by the patient for participation in the study and agreement&#xD;
             to comply with the follow-up schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute infection(s)&#xD;
&#xD;
          -  Known coagulation disorder&#xD;
&#xD;
          -  Allergies to nickel and/or titanium and/or nickel/titanium-related material, if not&#xD;
             medically manageable&#xD;
&#xD;
          -  Inability to achieve adequate oral anticoagulation therapy and/or platelet inhibition&#xD;
             post intervention&#xD;
&#xD;
          -  Intolerance to contrast agents, if not medically manageable&#xD;
&#xD;
          -  Participation in another clinical investigation &lt;30 days before intended Occlutech PFO&#xD;
             Occluder implantation procedure (note that in line with Medical Device Reporting,&#xD;
             registries are not considered as clinical investigations)&#xD;
&#xD;
          -  Contraindication to use of trans-esophageal echocardiography (TEE) and/or use of&#xD;
             general anesthetic&#xD;
&#xD;
          -  Eisenmenger Syndrome&#xD;
&#xD;
          -  Recent pelvic venous thrombosis&#xD;
&#xD;
          -  Myocardial infarction or coronary artery bypass surgery within the last 30 days&#xD;
&#xD;
          -  Atrial thrombus&#xD;
&#xD;
          -  Patients whose size or condition would cause them to be a poor candidate for cardiac&#xD;
             catheterization (e.g. too small for echocardiography imaging probe, catheter size,&#xD;
             vasculature size, active infection, body weight &lt;8 kg)&#xD;
&#xD;
        The following exclusion criteria are at the discretion of the investigator:&#xD;
&#xD;
          -  Stroke of any other origin&#xD;
&#xD;
          -  Large artery atherosclerosis&#xD;
&#xD;
          -  Small vessel disease&#xD;
&#xD;
          -  Arterial dissection&#xD;
&#xD;
          -  Hypercoagulable disorder&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Evidence of drug or alcohol abuse&#xD;
&#xD;
          -  Chronic, persistent, or paroxysmal atrial fibrillation or atrial flutter&#xD;
&#xD;
          -  End-stage heart-, liver-, lung-, or kidney disease&#xD;
&#xD;
          -  Cardiac tumor&#xD;
&#xD;
          -  Endocarditis or septicemia&#xD;
&#xD;
          -  Severe valvular pathology&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, might interfere with the&#xD;
             implantation,might affect the patients' well-being thereafter or might interfere with&#xD;
             the conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gönül Sönmez Utkun</last_name>
    <phone>+90 2124650497</phone>
    <email>clinicaltrials@occlutech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carere Ronald, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Schnupp, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden Universitätsklinik an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Woitek, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Zeus, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CardioVasculäres Centrum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horst Sievert, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Pfister, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Trabattoni, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

